1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics, November 2019

Cancer Analysis & Statistics, November 2019

1-30 of about 100 reports

Cyramza

Cyramza

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewCyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Nexavar

Nexavar

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewNexavar (sorafenib; Bayer/Amgen) is an orally available, multi-targeted tyrosine kinase inhibitor that is directed against several targets, including CRAF, BRAF, RET, KIT, FMS-like tyrosine ...

  • Industries : Pathology, Cancer, Therapy
  • Countries : United States, Japan, European Union
Tecentriq

Tecentriq

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewTecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union
Opdivo

Opdivo

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewOpdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Lenvima

Lenvima

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewLenvima (lenvatinib; Eisai/Merck and Co) is an orally available small molecule inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Keytruda

Keytruda

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewKeytruda (pembrolizumab; Merck and Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Stivarga

Stivarga

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewStivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently approved for the treatment of previously treated hepatocellular carcinoma patients. It ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Cabometyx

Cabometyx

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewCabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of multiple ...

  • Industries : Pathology, Cancer
  • Countries : United States, Japan, European Union
Imfinzi

Imfinzi

  • $ 10000
  • Industry report
  • September 2019

Drug OverviewImfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), ...

  • Industries : Pathology, Cancer
  • Countries : European Union, Japan, United States
2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

2019 Biomedtracker / Datamonitor Healthcare Post-ESMO Report

  • $ 4750
  • Industry report
  • October 2019

The Annual European Society for Medical Oncology (ESMO) 2019 Congress was held in Barcelona, Spain from September 27 to October 1, 2019. Conference highlights included new data from PARP inhibitors in ...

  • Industries : Cancer, Pathology
Market Spotlight: Hodgkin’s Lymphoma, Pharma Intelligence

Market Spotlight: Hodgkin’s Lymphoma, Pharma Intelligence

  • $ 1318
  • Industry report
  • October 2019

This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, key upcoming and regulatory events, recent events and analyst opinion, ...

  • Industries : Cancer, Pathology
  • Countries : World, United States
Market Spotlight: Sarcoma, Pharma Intelligence

Market Spotlight: Sarcoma, Pharma Intelligence

  • $ 1318
  • Industry report
  • September 2019

This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, recent events ...

  • Industries : Cancer, Pathology
  • Countries : World
Market Spotlight: Glioblastoma

Market Spotlight: Glioblastoma

  • $ 1318
  • Industry report
  • September 2019

This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability ...

  • Industries : Cancer, Pathology
  • Countries : United States, World
Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

Market Spotlight: NHL: Peripheral T-cell lymphoma (PTCL)

  • $ 1318
  • Industry report
  • September 2019

This Market Spotlight report covers the Peripheral T-Cell Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, patent information, a 10-yea ...

  • Industries : Cancer
  • Countries : World
Market Spotlight: Tumor Lysis Syndrome (TLS), Pharma Intelligence

Market Spotlight: Tumor Lysis Syndrome (TLS), Pharma Intelligence

  • $ 1318
  • Industry report
  • September 2019

This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed drugs, clinical trials, patent information, and a 10-year disease incidence forecast, as well as presenting ...

  • Industries : Cancer
  • Countries : World
Market Spotlight: Esophageal Cancer, Pharma Intelligence

Market Spotlight: Esophageal Cancer, Pharma Intelligence

  • $ 1318
  • Industry report
  • September 2019

This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.Key ...

  • Industries : Cancer, Pathology
Triple-Negative Breast Cancer KOL Interview – US

Triple-Negative Breast Cancer KOL Interview – US

  • $ 599
  • Industry report
  • October 2019

A US-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease ...

  • Industries : Therapy, Oncology
  • Countries : United States
Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

Prostate Cancer Diagnostics and Minimally Invasive Treatments Market

  • $ 4750
  • Industry report
  • July 2019

This report includes a discussion of leading products, new technologies, market forecasts, drivers and limiters, competitors, trends and opportunities in the nearly $1bn Prostate Cancer Diagnostics and ...

  • Industries : Cancer, Pathology, Diagnostics
  • Countries : United States, Japan
Bladder Cancer KOL Interview – US

Bladder Cancer KOL Interview – US

  • $ 599
  • Industry report
  • May 2019

A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

  • Industries : Cancer, Pathology
  • Countries : United States
Afinitor

Afinitor

  • $ 10000
  • Industry report
  • March 2019

Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Sutent

Sutent

  • $ 10000
  • Industry report
  • March 2019

Sutent (sunitinib; Pfizer) is an orally available multi-targeted tyrosine kinase inhibitor which specifically inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth facto ...

  • Industries : Cancer, Therapy, Pathology
  • Countries : United States, Japan, European Union
Votrient

Votrient

  • $ 10000
  • Industry report
  • March 2019

Votrient (pazopanib; Novartis) is an oral angiogenesis inhibitor targeting the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and c-KIT. Preclinical ...

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Avastin

Avastin

  • $ 10000
  • Industry report
  • March 2019

Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Inlyta

Inlyta

  • $ 10000
  • Industry report
  • March 2019

Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1.

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Torisel

Torisel

  • $ 10000
  • Industry report
  • March 2019

Torisel (temsirolimus; Pfizer) is an inhibitor of mammalian target of rapamycin (mTOR), which is an intracellular protein that has been implicated in multiple growth-related cellular functions.

  • Industries : Cancer, Pathology
  • Countries : United States, Japan, European Union
Fotivda

Fotivda

  • $ 10000
  • Industry report
  • March 2019

Drug OverviewFotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, and VEGFR-3. ...

  • Industries : Cancer, Therapy, Pathology, Drug Development
  • Countries : United States
abexinostat

abexinostat

  • $ 10000
  • Industry report
  • March 2019

Drug OverviewAbexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids ...

  • Industries : Cancer, Pathology
  • Countries : United States
CB-839

CB-839

  • $ 10000
  • Industry report
  • March 2019

Drug OverviewCancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine ...

  • Industries : Cancer, Therapy, Pathology, Oncology
  • Countries : United States, Japan, European Union
Renal cell cancer (RCC) disease forecast and market analysis to 2038

Renal cell cancer (RCC) disease forecast and market analysis to 2038

  • $ 22000
  • Industry report
  • March 2019

DISEASE OVERVIEWRenal cell carcinoma (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney ...

  • Industries : Cancer, Pathology
  • Countries : United States, European Union, Japan
Market Spotlight: Cervical Cancer, Pharma Intelligence

Market Spotlight: Cervical Cancer, Pharma Intelligence

  • $ 1318
  • Industry report
  • February 2019

This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, ...

  • Industries : Cancer, Pathology
  • Countries : World

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on